Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFPT1 | Q06210 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20192957 | 0.81 | GFPT1 (0.37) | GFPT1 | |
| SCHEMBL16447372 | 0.80 | GFPT1 (0.34) | GFPT1 | |
| SCHEMBL20178594 | 0.80 | GFPT1 (0.34) | GFPT1 | |
| SCHEMBL15469229 | 0.74 | GFPT1 (0.38) | GFPT1 | |
| SCHEMBL20192894 | 0.74 | SLC1A3 (0.42) | GFPT1 | |
| SCHEMBL15469218 | 0.73 | GFPT1 (0.36) | GFPT1 | |
| SCHEMBL17852316 | 0.71 | GFPT1 (0.41) | GFPT1 | |
| SCHEMBL22180584 | 0.70 | OTC (0.36) | GFPT1 | |
| SCHEMBL15469217 | 0.68 | CASR (0.37) | GFPT1 | |
| SCHEMBL31688850 | 0.66 | NOS2 (0.58) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9981908-B2 | Amino acid derivatives | MEDIMMUNE LIMITED (GB) | 2018-05-29 | — | — | US | disclosed |
| US-20160176811-A1 | Amino Acid Derivatives | ALLOZYNE, INC. | 2016-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160176811-A1 | Amino Acid Derivatives | BCAT2, BCAT1, DAO | GFPT1 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.